New Zealand · Delayed Price · Currency is NZD Ryman Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
A refreshed strategy prioritizes sustainable recurring earnings, operational excellence, and disciplined capital management, targeting NZD 150 million in cash flow improvement and NZD 500 million in cash release by FY 2029. Portfolio optimization, product innovation, and a new dividend policy underpin long-term value creation.
-
Positive free cash flow and 13% revenue growth were achieved, with cost savings ahead of target and refinancing completed. Sales guidance was updated, margins moderated due to market conditions, and significant cash release opportunities remain in inventory and development assets.
Fiscal Year 2025
-
The AGM addressed significant financial losses, a major board and executive refresh, and a strategic reset focused on cash generation, cost reduction, and disciplined growth. Shareholders engaged robustly on development risks, capital management, and future dividends, with management emphasizing transparency and a path to recovery.
-
FY 2025 saw operational reset, improved free cash flow, and a strengthened balance sheet after a major equity raise. Sales and pricing were stable, with cost reductions underway and a focus on cash release from stock and land. Guidance points to improved performance in FY 2026.
-
Leadership transition and major accounting changes marked the period, with a net loss before tax and fair value movements, compressed margins, and negative free cash flow guidance as settlements are deferred. Cost savings and operational improvements are underway amid challenging market conditions.
Fiscal Year 2024
-
Revenue rose but profits fell sharply due to impairments and higher costs, prompting a focus on cash flow, capital discipline, and operational efficiency. Board renewal, auditor change, and sustainability initiatives were key themes, with dividends suspended and strategic reviews ongoing.